DIAGNOSTIC CAPABILITIES OF SPECT/CT IN THE BONE METASTATIC DISEASE DETECTION IN PATIENTS WITH BREAST CANCER AND PROSTATE CANCER

Abstract

Purpose. To assess the additional contribution of SPECT/CT, used in conjunction with planar osteoscintigraphy, in bone metastatic disease detection and its effect on the tactics of managing patients with breast cancer and prostate cancer. Materials and methods. The study included 1412 patients with established oncological diagnosis (breast cancer — 844 patients, prostate cancer — 568 patients), to which «whole body» planar osteoscintigraphy, and SPECT/CT were performed. In all patients included in the study, the fact of bone metastatic disease was established by the results of additional imaging techniques and follow up. Results. Bone metastatic disease was detected in 324 (23%) patients and excluded in 1088 (77%). SPECT/CT had higher diagnostic indices than planar osteoscintigraphy. Sensitivity, specificity and accuracy of bone metastatic disease detection of planar osteoscintigraphy were 91%, 71%, 76%, of SPECT/CT, 97%, 93%, 94%, respectively. The additional use of SPECT/CT in the second stage after the planar osteoscintigraphy in 337 (24%) patients from the general group (n=1412) led to a change in the results of the diagnostic test. Conclusions. The additional use of SPECT / CT in the second stage after the planar osteoscintigraphy allows to change the results of the diagnostic test in the evaluation of bone metastatic disease in patients with breast cancer and PCa, which can significantly affect the management tactics of patients.